GlassScriptPhysician profile
Amit Malhotra
NPI 1699724294
$10,281.20
in general payments reported to CMS, 2019-2025
40 companies · $1,443 in 2025
The $1,443 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $414 · 2021: $854 · 2022: $1,577 · 2023: $2,047 · 2024: $2,261 · 2025: $1,443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,750.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,259.72 | 2019-2025 | Cardiomems, Mitraclip, Jeti |
| Philips North America LLC | $1,108.80 | 2019-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Astrazeneca Pharmaceuticals LP | $998.17 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $866.52 | 2019-2025 | |
| Medtronic, INC. | $527.54 | 2021-2025 | Endurant Iis, Aurora Ev-Icd Mri Surescan |
| Pfizer INC. | $472.93 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $458.97 | 2022-2025 | Amvuttra, Onpattro |
| Amgen INC. | $448.25 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $367.43 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $357.81 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $314.71 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $275.49 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $267.18 | 2019-2025 | Lifevest |
| Cardiovascular Systems INC. | $245.93 | 2019 | |
| Novo Nordisk INC | $191.39 | 2024-2025 | Wegovy, Ozempic |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $169.40 | 2023 | Optimizer, Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.57 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $165.77 | 2019-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $154.77 | 2021-2025 | |
| Shockwave Medical, INC | $154.19 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $144.02 | 2025 | Acticor 7 Vr-T Dx, Solia, Biomonitor |
| Sanofi-Aventis U.S. LLC | $143.41 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $129.79 | 2019-2024 | Xarelto |
| Cvrx, INC. | $128.56 | 2024-2025 | Barostim Neo System |
| Vifor Pharma, INC. | $121.92 | 2019 | |
| Terumo Medical Corporation | $98.44 | 2019 | |
| Esperion Therapeutics, INC. | $98.31 | 2024-2025 | Nexletol |
| Amarin Pharma, INC. | $94.27 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $76.87 | 2021-2024 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $65.68 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $38.46 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $30.36 | 2021 | |
| Bardy Diagnostics, INC. | $30.00 | 2021 | |
| Daiichi Sankyo INC. | $24.32 | 2025 | Injectafer |
| Bridgebio Pharma, INC. | $24.29 | 2025 | Attruby |
| Portola Pharmaceuticals, LLC | $21.37 | 2020 | |
| Lundbeck LLC | $21.10 | 2019 | |
| Irhythm Technologies, INC. | $16.49 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,425.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.